9:00-10:30Session I | Minimal residual disease
Chairpersons:Fabio Puglisi
Guilia Buzzati
9:00-9:30Can we move from probability to personalization in the adjuvant and neoadjuvant settings?
Massimo Cristofanilli
9:30-10:00Current technologies: opportunities and caveats
Umberto Malapelle
10:00-10:30Discussion
10:30-11:00Coffee break
11:00-12:30SESSION II | New therapeutic approaches
Chairpersons:Maria Vittoria Dieci
Giulia Antoniali
11:00-11:30New translational plafrorms and clinical trial designs
Luca Malorni
11:30-12:00New targets and drug screening strategies
Gustavo Baldassarre
12:00-12:30Discussion
12:30-14:30SESSION III | Networking lunch
12:30-13:00Liquid biopsy
Lorenzo Gerratana
Giulia Buzzatti
13:00-13:30Organoids and CTCs coltures
Giulia Brisotto
Giulia Gallerani
13:30-14:00Immunotargets and Microbiota
Giulia Antonialli
Elena Muraro
14:00-14:30Treatment resistance and Pharmaco-personalization
Rossana Roncato
Luca Mazzarella
14:30-15:30SYMPOSIUM
14:30-15:30From resistance factor to targetable alteration: ESR1 and the endocrine treatment algorithm
Interviews: Fabio Puglisi
Panel: Massimo Cristofanilli, Marzia Del Re, Lorenzo Gerratana, Umberto Malapelle
15:30-16:30SESSION IV | New perspectives for research and development
Chairpersons:Gianluca Tell
Marzia Del Re
15:30-15:50Treatment resistance models and drug develpment: from hypothesis generation to clinical applicability and investigation
Luca Mazzarella
15:50-16:10The future is multiparametric: emerging applications and new scenarios in liquid biopsy
Lorenzo Gerratana
16:10-16:30Discussion
16:30Closing remarks
The management of patients with breast cancer has evolved significantly in recent years, with a shift to a highly personalized treatment paradigm. This novel approach is reliant on the growing introduction of new drugs directed at specific molecular targets, requiring the concomitant design of more sophisticated and dynamic biomarkers. Such developments require increasingly integrated algorithms encompassing experts with multiple backgrounds, as well as constant interdisciplinary contamination.
Leggi
The “Focus on TOP” symposium aims to introduce an innovative format in tune with this new context. The event will feature presentations from opinion leaders coming from both the clinical and preclinical settings, as well as a critical analysis of the state of the art in research and development.
The design of interactive workshops aimed at boosting networking and brainstorming will be the centerpiece of this meeting. The discussions will promote debate and interdisciplinary col- laboration, with the goal of establishing new synergies that are crucial to the development of new biomarkers and therapeutic options.
To expand on this, the networking phase will be followed by a session dedicated to new development perspectives, guided by top emerging experts, with the goal of setting the basis and encouraging interactive discussion between trainees and mentors.